RT期刊文章SR电子T1使用Tiotopium respimat软雾吸入器相对COPD JF欧洲呼吸杂志患者的Handihaler和死亡率JO EUR呼吸J FD欧洲呼吸学会SP 606 OP 615 DO 10.1183/09031936.00005813 VO 42 V188bet官网地址O 42 IS 3 A1 Verhamme，Katia M.C.A1 Afonso，Ana A1 Romio，Silvana A1 Stricker，Bruno C. A1 Brusselle，Guy G.O. A1 Sturkenboom，Miriam C.J.M.YR 2013 UL //www.qdcxjkg.com/content/42/3/606.abstract ab tiotropium是一种长效的抗胆碱能，通过Handihaler或Rescimat进行交付。随机对照试验表明，使用tiotimatimat会增加死亡的风险。我们比较了tiotimat tiotimat与Handihaler之间死亡的风险。在综合的初级保健信息数据库中，我们定义了≥40岁的患者的来源人群，随访≥1岁。根据处方数据，我们定义了tiotopium使用的发作（Respimat或Handihaler）。在这些事件中，使用COX比例危害回归分析计算死亡率的风险。从来源人群中，有11名287名患者提供了24522次促粒细胞的发作。496名患者在接触Handihaler或Respimat时死亡。 Use of Respimat was associated with almost 30% increased risk of dying (adjusted HR 1.27, 95% CI 1.03–1.57) with the highest risk for cardiovascular/cerebrovascular death (adjusted HR 1.56, 95% CI 1.08–2.25). The risk was higher in patients with co-existing cardiovascular disease (adjusted HR 1.36, 95% CI 1.07–1.73) than in patients without (adjusted HR 1.02, 95% CI 0.61–1.71). Use of tiotropium Respimat was associated with an almost 30% increase of mortality compared with HandiHaler and the association was the strongest for cardiovascular/cerebrovascular death. It is unclear whether this association is causal or due to residual confounding by chronic obstructive pulmonary disease severity. Tiotropium Respimat was associated with a 30% increase in mortality compared with HandiHaler in COPD http://ow.ly/mpmhp